GASTRIC CANCER

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This early-phase trial tested a new drug called RO7496353 combined with an immunotherapy (atezolizumab) and sometimes chemotherapy in 102 people with advanced lung, stomach, or pancreatic cancer. The main goal was to check safety and side effects. Researchers also looked at how t…

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…

This phase 2 trial tested a combination of radiation, a targeted drug (olaparib), and an immunotherapy (pembrolizumab) in 9 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if this approach could shrink tumors that were not dir…

This phase 2 study tested a combination of two drugs, pembrolizumab and ramucirumab, in 26 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if the combo could shrink tumors or slow the disease. Participants received both drugs …

This phase II trial tested a combination of three treatments: specially engineered natural killer cells (PD-L1 CAR-NK cells), an immunotherapy drug (pembrolizumab), and an immune booster (N-803) in 18 adults with advanced gastric or head and neck cancer that had not responded to …

This phase 3 trial tested whether adding a targeted drug called bemarituzumab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer that has a specific protein (FGFR2b). The study enrolled 547 adults whose cancer could not be removed by s…

This study tested whether adding intravenous (IV) nutrition to standard oral supplements helps patients who had stomach cancer surgery recover better. 55 adults were randomly assigned to get either the combined nutrition or standard care. The main goal was to see if the combo app…

This pilot study tested a combination of chemotherapy drugs (FOLFIRINOX plus paclitaxel and carboplatin) along with proton beam radiation before surgery in 25 people with gastroesophageal cancer. The goal was to see if this intense pre-surgery treatment could shrink tumors and be…

This study tested a drug called savolitinib in 110 people with advanced stomach or esophagus-stomach junction cancer whose tumors have a specific genetic change (MET gene amplification). The goal was to see if the drug could shrink tumors and how safe it was. Participants receive…

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This early-phase study tested a new treatment using immune cells from cord blood, modified to target a protein called Claudin18.2 found on some cancer cells. Ten adults with advanced stomach or pancreatic cancer who had no other options received these cells to find the safest dos…

This completed study by Pfizer tested a biosimilar (a near-copy) of trastuzumab in 8 people with advanced or recurrent HER2-positive gastric cancer that could not be removed by surgery. The goal was to check safety and how well the drug worked in real-world use. Participants rece…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This completed Phase 2 trial tested whether a special DNA-based test could predict how well patients with stomach or rectal cancer respond to immunotherapy (tislelizumab) combined with chemotherapy and/or radiation. 189 adults with advanced cancer participated. The goal was to se…

This completed Phase 2 study tested a combination of chemotherapy (FOLFIRI) and radiation with 5-fluorouracil in 63 patients with gastric cancer. The treatment was given either before or after surgery to remove the tumor. The goal was to see if this approach is feasible and less …

This early-stage study tested a new drug called cabotamig in 33 adults with advanced cancers of the digestive system (like colon, pancreas, or liver) that had stopped responding to standard treatments. The goal was to see if the drug is safe and how it affects the body and tumors…

This study tested whether a personalized nutrition plan, including extra amino acids, could improve muscle quality and recovery in 40 men undergoing surgery for gastric cancer. Half received standard care, and half received a tailored supplement. The goal was to see if this appro…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery helps people with stomach or gastroesophageal junction cancer. Over 1,000 participants received either pembrolizumab plus chemo or placebo pl…

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug combination or a placebo before and after surgery. The goal was to see if the combination improve…

This phase 2 study tested a combination of two drugs, TAS 102 (Lonsurf) and ramucirumab (Cyramza), in 23 patients with advanced stomach or gastroesophageal junction cancer that had stopped responding to other treatments. The goal was to see if the combo was safe and could help pa…

This study tested whether a longer intestinal bypass during stomach cancer surgery improves diabetes control better than the standard method. It included 94 adults with early-stage gastric cancer and type 2 diabetes. Researchers measured blood sugar and hormone levels one year af…

This study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…

This study compared two types of surgery for stomach cancer: laparoscopic (keyhole) and open surgery. The goal was to see if keyhole surgery leads to a shorter hospital stay and fewer complications. The trial included 210 patients with resectable stomach cancer and is now complet…

This early-phase study tested a new drug called SHR-A1811 in 101 people with advanced stomach or colorectal cancers that have a specific protein called HER2. The main goals were to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants h…

This early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…

This early-phase trial tested a new drug called CUE-102 in 42 adults with certain advanced cancers (colorectal, gastric, pancreatic, or ovarian) that had returned or spread despite prior treatments. The drug is designed to help the immune system attack cancer cells that carry a s…

This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…

This study tested a new treatment combination (GEN-001 plus avelumab) in 42 people with advanced stomach or gastroesophageal junction cancer that had not responded to at least two prior therapies. All participants had a specific marker (PD-L1 positive) on their tumors. The goal w…

This phase 2 trial tested a combination of two drugs—telatinib (a pill that blocks tumor blood vessels) and Keytruda (an immunotherapy that helps the immune system attack cancer)—in 16 people with advanced stomach, gastroesophageal junction, or liver cancer. The goal was to see i…

This phase 2 trial tested a combination of two chemotherapy drugs (capecitabine and oxaliplatin) plus two targeted antibodies (bevacizumab and trastuzumab) in 37 people with HER2-positive stomach or esophageal cancer that had spread. The goal was to see how safe and effective the…

This study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer that had lost a protein called E-cadherin. It also tested crizotinib alone in people with diffuse gastric cancer, triple-negative lobular breast cancer, or o…

This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors …

This early-stage trial tested a new drug called vibostolimab, either alone or combined with other cancer drugs, in 474 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the dr…

This study tested a doctor-designed dose adjustment algorithm to prevent unplanned delays in FOLFOX chemotherapy for people with cancers of the colon, stomach, esophagus, and other digestive organs. 52 adults participated, and the goal was to see if the algorithm could keep treat…

This study tested a new drug called SAR444245 combined with other cancer treatments in 138 adults with advanced gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancer. The goal was to see if the combination could shrink tumors. The study is complete…

This study tested a new treatment for stomach cancer that has spread to the lining of the abdomen. The approach combines standard chemotherapy with a procedure called PIPAC, which delivers chemotherapy as a pressurized aerosol directly into the abdomen during a keyhole surgery. T…

This phase 2 study tested a new drug, FLX475, combined with the immunotherapy pembrolizumab (Keytruda) in 20 people with advanced or metastatic stomach cancer. The goal was to see if the combination could shrink tumors in patients who had already tried other treatments. The study…

This Phase 3 trial tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy, followed by camrelizumab plus the targeted drug apatinib, helps people with advanced stomach or gastroesophageal junction cancer live longer. The study enrolled 885 participants…

This pilot study tested a new radioactive tracer called 89Zr-DFO*-trastuzumab in 6 people with HER2-positive breast or gastric cancer. The tracer is designed to attach to HER2 proteins on cancer cells and show up on PET scans. Participants received one injection and had up to 4 P…

This completed study looked at whether a special PET scan using 18F-FDG can help doctors more accurately diagnose, stage, and track stomach cancer. Researchers studied 50 patients with confirmed gastric cancer, comparing scan results to other tests. The goal was to see if this im…

This study looked at a new test called OSNA to find free cancer cells in the belly fluid of 108 people with stomach or colon cancer who had no visible spread. The goal was to see if OSNA could detect cancer cells better than the usual lab method. If successful, this could help do…

This study tested a new radioactive tracer called [18F]FAPI-74 for PET scans in people with gastrointestinal cancers, including liver, bile duct, stomach, pancreatic, and colorectal cancers. The goal was to see if the tracer can accurately detect cancer cells by comparing scan re…

This study tested a new type of PET scan (FAPI) in 20 people with stomach or gastro-esophageal junction cancer. The goal was to see if FAPI scans are more accurate than standard scans for determining the cancer stage before and after chemotherapy. By comparing scan results with t…

This study tested a training system for confocal laser endomicroscopy (CLE), a technique that lets doctors see cells in real time during an endoscopy. 147 patients with stomach lesions were examined by both experts and trainees. The goal was to see if the training helped doctors …

This trial compares two minimally invasive surgical techniques for removing the lower part of the stomach in people with gastric cancer: laparoscopy-assisted distal gastrectomy (LADG) and totally laparoscopic distal gastrectomy (TLDG). The goal is to see which approach leads to b…

This study tested a drug called M701, given directly into the belly, combined with standard cancer therapy, for people with malignant ascites (fluid buildup) from stomach, colon, or ovarian cancer. The goal was to see if M701 could delay the need for fluid drainage and improve su…

This study compared two methods of pain control after open stomach surgery: a nerve block (rectus sheath block) using bupivacaine versus standard epidural pain relief. Sixty adults scheduled for elective open gastrectomy were randomly assigned to one of the two groups. The resear…

This study tested whether silkworm pupa tablets can improve nutrition and reduce frailty in people who had surgery for stomach, colorectal, esophageal, or pancreatic cancer. 120 participants took the tablets for 3 months. Researchers measured weight, frailty, muscle mass, and qua…

This study looked at whether having a palliative care team work alongside surgeons improves quality of life for patients with gastrointestinal cancers like pancreatic or liver cancer. About 379 patients and their family members took part. The main goal was to see if this team app…

This study looked at whether having a special consultation with a radiotherapy technician (called a manipulator) helps cancer patients feel more informed about their treatment. Researchers enrolled 308 adults with various cancers who were getting radiation therapy. They compared …

This study follows up on over 32,900 people from Linxian, China, who took part in a nutritional trial between 1985 and 1991. Researchers are tracking cancer cases and deaths to see if earlier vitamin and mineral supplements had lasting effects. They are also collecting blood samp…

This study looked at 60 people having stomach cancer surgery to see if adding an epidural to general anesthesia changes how much muscle relaxant is needed and how fast it wears off. Half got general anesthesia alone, half got general anesthesia plus a thoracic epidural. Researche…

This study tracked 295 adults who had high-risk surgery for stomach, esophagus, pancreas, or liver cancer. Researchers measured quality of life before surgery and again at 6 and 12 months after. They also asked patients and their family members if they regretted the decision to h…

This pilot study looked at whether repeated FDG-PET/CT scans can help select patients and evaluate how well a special chemotherapy (PIPAC) works for cancer that has spread to the lining of the abdomen. 34 patients with various abdominal cancers were included. The goal was to see …

This study looked at why many cancer patients lose muscle and weight, a condition called cachexia. Researchers collected samples of muscle, fat, blood, and urine from 282 people during cancer surgery and compared them with samples from non-cancer patients. They also measured phys…

This study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…

This completed study observed 178 patients with advanced cancer, chronic kidney failure, or chronic lung diseases to assess their palliative care needs and survival factors. Researchers used two scoring tools to evaluate when and how to best introduce palliative care alongside re…

This study looked back at medical records of 260 adults in China with advanced stomach or gastroesophageal junction cancer who received nivolumab as their first treatment. The goal was to see how well the drug worked in everyday practice and what treatment patterns were used. No …

This study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…

This study tested a risk scoring model to predict whether stomach cancer might spread to the liver after surgery. Researchers followed 120 patients who had their stomach cancer removed to see if the model could accurately identify those at higher risk. The goal is to help doctors…

This study tested over 1,000 people in Bhutan for H. pylori, a stomach infection that can lead to stomach cancer. Researchers measured infection rates and stomach damage to understand the problem and plan a national prevention program. Participants were from rural villages, and t…

This study tested a risk scoring model that predicts whether stomach cancer has spread to nearby lymph nodes before surgery. Researchers looked at data from 120 patients who had their stomach cancer removed. The goal was to see if the model could help doctors make better treatmen…